Dogmas and Controversies in Hematologic Malignancies: Los Angeles

Redondo Beach, CA US
March 28, 2025 to March 29, 2025

Dogmas and Controversies in Hematologic Malignancies: Los Angeles is an annual 2-day CME-accredited conference featuring leading experts who will deliver a comprehensive review of current and emerging strategies for managing Hodgkin and non-Hodgkin lymphoma, chronic lymphocytic leukemia, acute leukemias, myeloproliferative neoplasms, and multiple myeloma.

This program aims to enhance participants’ knowledge and competence in applying practice-changing clinical data and expert recommendations to optimize outcomes for patients with hematologic malignancies. Through scientific debates, panel discussions, and in-depth analysis, the conference will address key controversies and advances in the field, with a focus on integrating innovative therapies into clinical practice. Designed for a multidisciplinary audience of physicians, advanced practice providers, pharmacists, nurses, and other healthcare professionals, the conference emphasizes evidence-based approaches and a patient-centered care model. Participants will gain actionable insights to improve clinical outcomes and stay informed on the latest developments in hematologic malignancies.

Target Audience

  • Cancer care professionals
  • Medical Oncologists and Hematologists
  • Medical oncology and hematology fellows
  • Oncology nurses
  • Nurse practitioners
  • Physician assistants
  • Pharmacists

Organizing Committee 

Conference Director: 

Binay Shah, MD, MHA - Binaytara Foundation

Conference Chairs: 

Alexey V. Danilov, MD, PhD - City of Hope Medical Center

Thomas G. Martin, MD - UCSF Helen Diller Family Comprehensive Cancer Center

Vinod Pullarkat, MD, MRCP - City of Hope Medical Center

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review strategies for initial therapy and therapies for relapsed disease for patients with various hematologic malignancies
  • Outline efficacy and toxicities of small molecule inhibitors, monoclonal antibodies, antibody drug conjugates, T-cell redirecting bispecific antibodies, and CAR-T for the treatment of patients with hematologic malignancies
  • Apply an individualized treatment plan for patients with ALL, AML, CML, MPN, MM, NHL, HL, based on patient- and disease-related factors 
  • Review evolving role of autologous and allogeneic stem cell transplantation in different hematologic malignancies

HOTEL INFORMATION

COMING SOON

GLOBAL ONCOLOGY PROJECT

To learn more about our ongoing project building a 200-bed cancer hospital in Nepal.

Course summary
Available credit: 
  • 10.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 10.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 10.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 10.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 10.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 10.50 Contact Hours.
Course opens: 
10/08/2024
Course expires: 
07/25/2025
Event starts: 
03/28/2025 - 8:00am PDT
Event ends: 
03/29/2025 - 3:30pm PDT
Cost:
$350.00
Add to calendar: 

DAY 1 - Friday, March 28th, 2025

All times listed in Pacific Time Zone (PT)
 

12:30 PM – 01:30 PM  Registration, Networking, & Exhibits

01:30 PM – 01:50 PM  Plenary Lecture - Next Generation CAR T-Cell Therapeutics

01:50 PM – 02:00 PM  Q & A

02:00 PM – 03:30 PM  Session 1 - Non-Hodgkin's Lymphoma

Session Chair: Alexey Danilov, MD, PhD 

02:00 PM – 02:15 PM  Have BTK Inhibitors Replaced Transplant in MCL? - Tycel Phillips, MD

02:15 PM – 02:30 PM  DLBCL: Is There Still a Role for Autologous Transplant? - Javier Munoz, MD, MBA

02:30 PM – 02:45 PM  T-cell lymphoma –promises of the future - Bradley Haverkos, MD

Debate: CAR-T versus Bispecifics in FL

    02:45 PM – 02:55 PM  CAR-T

    02:55 PM – 03:05 PM  Bispecifics - Swetha Kambhampati Thiruvengadam, MD

03:05 PM – 03:30 PM  Case-Based Presentation & Panel Discussion 

03:30 PM – 04:00 PM  Break & Exhibits

04:00 PM – 05:30 PM  Session 2 - Leukemia

Session Chair: Vinod Pullarkat, MD

04:00 PM – 04:15 PM  Doublets and Triplets: AML Induction in the Era of Targeted Therapies

04:15 PM – 04:30 PM  Menin Inhibitors: Next Best Thing Since Venetoclax?

04:30 PM – 04:45 PM  Low Risk MDS: Do New Approved Therapies Change Outcomes? - Brian Ball, MD

04:45 PM – 05:00 PM  Case Presentation

05:00 PM – 05:30 PM  Panel Discussion

05:30 PM – 06:30 PM  Reception, Networking, & Poster Abstracts

 
DAY 2 - Saturday, March, 29th, 2025
 

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits 

08:00 AM – 09:30 AM  Session 3 - Myeloma

Session Chair: 

08:00 AM – 08:15 AM  SMM – With All the New Data – Is Treatment More or Less Controversial? - Ajai Chari, MD

08:15 AM – 08:30 AM  Frontline Therapy for the “Frail” – How Do We Define Frail and Which Drugs to Combine?

08:30 AM – 08:45 AM  What is High-Risk MM? New Definition and Treatment? 

Debate: What is Best: Maintenance Therapy or Continuous Therapy for TE and TI MM?

    08:45 AM – 08:55 AM  Maintenance is Lenalidomide

    08:55 AM – 09:05 AM  Maintenance Should Include a CD38 Monoclonal Antibody

09:05 AM – 09:30 AM  Case-Based Discussion

09:30 AM – 10:00 AM  Break & Exhibits

10:00 AM – 11:30 AM  Session 4 - Leukemia

Session Chair: Vinod Pullarkat, MD

10:00 AM – 10:15 AM  Incorporating Blinatumomab into Frontline ALL Regimens? - Ryan Cassaday, MD

10:15 AM – 10:30 AM  CML: Which TKI? For How Long? -  Jerald Radich, MD

10:30 AM – 10:45 AM  Can CAR T Cure Adult ALL?

Debate: Stem Cell Transplant for Ph + ALL

    10:45 AM – 10:55 AM  Transplant is Outdated - Tamer Othman, MD

    10:55 AM – 11:05 AM  Transplant is Still Standard of Care

11:05 AM – 11:30 AM  Panel Discussion

11:30 AM – 11:45 AM  Session 5 - Global Oncology 

Improving Access to Hematology and Oncology in LMIC - Binaytara Foundation's Approach - Binay Shah, MD, MHA

11:45 AM – 12:30 PM Session 6 - APP Discussion: Treatment Toxicities - Practical Tips on Management

Session Chair:

Panel Discussion:

12:30 PM – 01:30 PM  Lunch & Exhibits

01:30 PM – 03:00 PM  Session 7 - Myeloma

Session Chair: 

01:30 PM – 01:45 PM  Current Results With CAR T-cell Therapy - Andrew Cowan, MD

01:45 PM – 02:00 PM  Current Results With Bispecific T-cell Engager Antibodies 

Debate: RRMM – What is the Best Therapy for Early Relapse MM

    02:00 PM – 02:10 PM  CAR T-cell Therapy Should Be First Choice for First or Subsequent Relapse

    02:10 PM – 02:20 PM  CAR T therapy Should Be Reserved for Late Relapse

02:20 PM – 02:35 PM  Exciting Agents (non-Immunotherapy) for Triple Class Refractory MM

02:35 PM – 03:00 PM  Case-Based Discussion

03:00 PM – 03:30 PM  Break & Exhibits

03:30 PM – 05:00 PM  Session 8 - CLL/LPL and HL

Session Chairs: Alexey Danilov, MD, PhD & Catherine Coombs, MD

03:30 PM – 03:45 PM  DLBCL: Embarrassment of Riches? Post-CAR T Space

03:45 PM – 04:00 PM  How I Treat LPL - Geoff Shouse, DO, PhD

04:00 PM – 04:15 PM  Evolution of Therapy in Richter's Syndrome - Benjamin Heyman, MD

Debate: CLL Progressing on BTK Inhibitors

    04:15 PM – 04:25 PM  Stay in Class - Catherine Coombs, MD

    04:25 PM – 04:35 PM  Switch Class - Mazyar Shadman, MD, MPH

04:35 PM – 05:00 PM  Panel Discussion 

05:00 PM  Adjourn

Sonesta Redondo Beach and Marina
300 North Harbor Drive
Redondo Beach, CA 90277
United States

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

Alexey Danilov, MD, PhD

has a financial relationship (Independent contractor) with Astra Zeneca;.
has a financial relationship (Independent contractor) with Lilly;.
has a financial relationship (Grant Or Contract) with Nurix;.
has a financial relationship (Independent contractor) with Beigene;.
has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Grant Or Contract) with MEI;.
Speaker/Topic Presenter(s)

Ryan Cassaday, MD

has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Grant Or Contract) with Servier;.
has a financial relationship (Independent contractor) with Kite;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Independent contractor) with Jazz;.
has a financial relationship (Independent contractor) with Autolus;.
has a financial relationship (Grant Or Contract) with Kite;.
has a financial relationship (Grant Or Contract) with Vanda;.
has a financial relationship (Other) with Autolus;.

Javier Munoz, MD MS MBA

has a financial relationship (Professional Services) with Pharmacyclics/Abbvie, Bayer, Gilead/Kite, Beigene, Pfizer, Janssen, Celgene/BMS, Kyowa, Alexion, Fosunkite, Seattle Genetics, Karyopharm, Aurobindo, Verastem, Genmab, Genzyme, Genentech/Roche, ADC Therapeutics, Epizyme, Beigene, Novartis, Morphosys/Incyte;.
has a financial relationship (Other) with Targeted Oncology, OncView, Curio, and Physicians' Education Resource;.
has a financial relationship (Financial Support) with Bayer, Gilead/Kite, Celgene, Merck, Portola, Incyte, Genentech, Pharmacyclics, Seattle Genetics, Janssen, Millennium, Novartis, Beigene;.
has a financial relationship (Professional Services) with MEI, TG Therapeutics, AstraZeneca, Eli Lilly;.

Tycel Phillips, MD

has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Independent contractor) with Kite;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with Beigene;.
has a financial relationship (Independent contractor) with Epizyme;.
has a financial relationship (Independent contractor) with Incyte;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Grant Or Contract) with Abbvie;.
has a financial relationship (Independent contractor) with Bayer;.
has a financial relationship (Independent contractor) with Eli Lily;.
has a financial relationship (Independent contractor) with Gilead;.
has a financial relationship (Independent contractor) with Xencor;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Independent contractor) with Astra Zeneca;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with Genmab;.
has a financial relationship (Independent contractor) with Pharmacyclics ;.
has a financial relationship (Independent contractor) with ADCT;.

Jerald Radich, MD

has a financial relationship (Other) with HTG;.
has a financial relationship (Stock Options) with Biofidelity;.

Geoffrey Shouse, DO, PhD

has a financial relationship (Independent contractor) with Beigene USA;.
has a financial relationship (Independent contractor) with Beigene USA;.
has a financial relationship (Independent contractor) with Kite Pharma;.
has a financial relationship (Independent contractor) with Kite Pharma;.
has a financial relationship (Independent contractor) with Astra Zeneca;.

Available Credit

  • 10.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 10.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 10.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 10.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 10.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 10.50 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.

Required Hardware/software

Morbi tristique senectus et netus et malesuada fames ac turpis.